Hodgkin disease/lymphoma

Richard T. Hoppe, Ranjana Hira Advani, Richard F. Ambinder, Philip Jay Bierman, Clara D. Bloomfield, Kristie Blum, Bouthaina Dabaja, Benjamin Djulbegovic, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Melissa M. Hudson, Mark S. Kaminski, Gena Love, David G. Maloney, David Mansur, Peter M. Mauch, Joseph O. Moore, Russell J. Schilder, Lawrence M. Weiss & 3 others Jane N. Winter, Joachim Yahalom, Andrew D. Zelenetz

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The management of HL continues to evolve. Major changes have been incorporated into these guidelines since inception. Current management of HL involves initial treatment with chemotherapy or combined modality therapy, followed by restaging to assess treatment response. PET scans are recommended to evaluate initial staging and assess treatment response at restaging. However, they are not recommended for routine surveillance. Combined modality therapy (brief course of chemotherapy and limited irradiation) is the preferred treatment for early-stage favorable CHL (stage IA-IIA nonbulky) and early-stage unfavorable CHL (stage I-II bulky). Chemotherapy alone or combined modality therapy is recommended for advanced-stage CHL (stage IB-IIB nonbulky and stage III-IV). Combined modality therapy or radiation alone is the option for early-stage LPHL. Patients with advanced-stage LPHL may be treated with more aggressive therapy. The role of chemotherapy or antibody-based therapy is being explored in ongoing clinical trials for early-and advanced-stage LPHL. HDT/ASCR is the best treatment option for patients with relapsed or refractory HL, although it does not improve overall survival. Consistent with NCCN philosophy, participation in clinical trials is always encouraged. HL is now curable in most patients because more effective, less toxic regimens have been introduced. However, survivors may experience late treatment-related side effects. For this reason, long-term follow-up by an oncologist is essential after completion of treatment. Counseling about survivorship issues and careful monitoring for late treatment-related side effects should be integral follow-up for these patients.

Original languageEnglish (US)
Pages (from-to)594-622
Number of pages29
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number6
StatePublished - Jul 1 2008

Fingerprint

Hodgkin Disease
Combined Modality Therapy
Therapeutics
Drug Therapy
Clinical Trials
Poisons
Positron-Emission Tomography
Survivors
Counseling
Survival Rate
Guidelines
Radiation
Survival
Antibodies

Keywords

  • Classical Hodgkin disease
  • Combined modality therapy
  • Hodgkin disease
  • Lymphocyte predominance
  • Lymphoma
  • NCCN clinical practice guidelines

ASJC Scopus subject areas

  • Oncology

Cite this

Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., Blum, K., ... Zelenetz, A. D. (2008). Hodgkin disease/lymphoma. JNCCN Journal of the National Comprehensive Cancer Network, 6(6), 594-622.

Hodgkin disease/lymphoma. / Hoppe, Richard T.; Advani, Ranjana Hira; Ambinder, Richard F.; Bierman, Philip Jay; Bloomfield, Clara D.; Blum, Kristie; Dabaja, Bouthaina; Djulbegovic, Benjamin; Forero, Andres; Gordon, Leo I.; Hernandez-Ilizaliturri, Francisco J.; Hudson, Melissa M.; Kaminski, Mark S.; Love, Gena; Maloney, David G.; Mansur, David; Mauch, Peter M.; Moore, Joseph O.; Schilder, Russell J.; Weiss, Lawrence M.; Winter, Jane N.; Yahalom, Joachim; Zelenetz, Andrew D.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 6, 01.07.2008, p. 594-622.

Research output: Contribution to journalReview article

Hoppe, RT, Advani, RH, Ambinder, RF, Bierman, PJ, Bloomfield, CD, Blum, K, Dabaja, B, Djulbegovic, B, Forero, A, Gordon, LI, Hernandez-Ilizaliturri, FJ, Hudson, MM, Kaminski, MS, Love, G, Maloney, DG, Mansur, D, Mauch, PM, Moore, JO, Schilder, RJ, Weiss, LM, Winter, JN, Yahalom, J & Zelenetz, AD 2008, 'Hodgkin disease/lymphoma', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. 6, pp. 594-622.
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K et al. Hodgkin disease/lymphoma. JNCCN Journal of the National Comprehensive Cancer Network. 2008 Jul 1;6(6):594-622.
Hoppe, Richard T. ; Advani, Ranjana Hira ; Ambinder, Richard F. ; Bierman, Philip Jay ; Bloomfield, Clara D. ; Blum, Kristie ; Dabaja, Bouthaina ; Djulbegovic, Benjamin ; Forero, Andres ; Gordon, Leo I. ; Hernandez-Ilizaliturri, Francisco J. ; Hudson, Melissa M. ; Kaminski, Mark S. ; Love, Gena ; Maloney, David G. ; Mansur, David ; Mauch, Peter M. ; Moore, Joseph O. ; Schilder, Russell J. ; Weiss, Lawrence M. ; Winter, Jane N. ; Yahalom, Joachim ; Zelenetz, Andrew D. / Hodgkin disease/lymphoma. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. 6. pp. 594-622.
@article{22815577d1a041b9ab5f8846a47a747b,
title = "Hodgkin disease/lymphoma",
abstract = "The management of HL continues to evolve. Major changes have been incorporated into these guidelines since inception. Current management of HL involves initial treatment with chemotherapy or combined modality therapy, followed by restaging to assess treatment response. PET scans are recommended to evaluate initial staging and assess treatment response at restaging. However, they are not recommended for routine surveillance. Combined modality therapy (brief course of chemotherapy and limited irradiation) is the preferred treatment for early-stage favorable CHL (stage IA-IIA nonbulky) and early-stage unfavorable CHL (stage I-II bulky). Chemotherapy alone or combined modality therapy is recommended for advanced-stage CHL (stage IB-IIB nonbulky and stage III-IV). Combined modality therapy or radiation alone is the option for early-stage LPHL. Patients with advanced-stage LPHL may be treated with more aggressive therapy. The role of chemotherapy or antibody-based therapy is being explored in ongoing clinical trials for early-and advanced-stage LPHL. HDT/ASCR is the best treatment option for patients with relapsed or refractory HL, although it does not improve overall survival. Consistent with NCCN philosophy, participation in clinical trials is always encouraged. HL is now curable in most patients because more effective, less toxic regimens have been introduced. However, survivors may experience late treatment-related side effects. For this reason, long-term follow-up by an oncologist is essential after completion of treatment. Counseling about survivorship issues and careful monitoring for late treatment-related side effects should be integral follow-up for these patients.",
keywords = "Classical Hodgkin disease, Combined modality therapy, Hodgkin disease, Lymphocyte predominance, Lymphoma, NCCN clinical practice guidelines",
author = "Hoppe, {Richard T.} and Advani, {Ranjana Hira} and Ambinder, {Richard F.} and Bierman, {Philip Jay} and Bloomfield, {Clara D.} and Kristie Blum and Bouthaina Dabaja and Benjamin Djulbegovic and Andres Forero and Gordon, {Leo I.} and Hernandez-Ilizaliturri, {Francisco J.} and Hudson, {Melissa M.} and Kaminski, {Mark S.} and Gena Love and Maloney, {David G.} and David Mansur and Mauch, {Peter M.} and Moore, {Joseph O.} and Schilder, {Russell J.} and Weiss, {Lawrence M.} and Winter, {Jane N.} and Joachim Yahalom and Zelenetz, {Andrew D.}",
year = "2008",
month = "7",
day = "1",
language = "English (US)",
volume = "6",
pages = "594--622",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "6",

}

TY - JOUR

T1 - Hodgkin disease/lymphoma

AU - Hoppe, Richard T.

AU - Advani, Ranjana Hira

AU - Ambinder, Richard F.

AU - Bierman, Philip Jay

AU - Bloomfield, Clara D.

AU - Blum, Kristie

AU - Dabaja, Bouthaina

AU - Djulbegovic, Benjamin

AU - Forero, Andres

AU - Gordon, Leo I.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Hudson, Melissa M.

AU - Kaminski, Mark S.

AU - Love, Gena

AU - Maloney, David G.

AU - Mansur, David

AU - Mauch, Peter M.

AU - Moore, Joseph O.

AU - Schilder, Russell J.

AU - Weiss, Lawrence M.

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Zelenetz, Andrew D.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The management of HL continues to evolve. Major changes have been incorporated into these guidelines since inception. Current management of HL involves initial treatment with chemotherapy or combined modality therapy, followed by restaging to assess treatment response. PET scans are recommended to evaluate initial staging and assess treatment response at restaging. However, they are not recommended for routine surveillance. Combined modality therapy (brief course of chemotherapy and limited irradiation) is the preferred treatment for early-stage favorable CHL (stage IA-IIA nonbulky) and early-stage unfavorable CHL (stage I-II bulky). Chemotherapy alone or combined modality therapy is recommended for advanced-stage CHL (stage IB-IIB nonbulky and stage III-IV). Combined modality therapy or radiation alone is the option for early-stage LPHL. Patients with advanced-stage LPHL may be treated with more aggressive therapy. The role of chemotherapy or antibody-based therapy is being explored in ongoing clinical trials for early-and advanced-stage LPHL. HDT/ASCR is the best treatment option for patients with relapsed or refractory HL, although it does not improve overall survival. Consistent with NCCN philosophy, participation in clinical trials is always encouraged. HL is now curable in most patients because more effective, less toxic regimens have been introduced. However, survivors may experience late treatment-related side effects. For this reason, long-term follow-up by an oncologist is essential after completion of treatment. Counseling about survivorship issues and careful monitoring for late treatment-related side effects should be integral follow-up for these patients.

AB - The management of HL continues to evolve. Major changes have been incorporated into these guidelines since inception. Current management of HL involves initial treatment with chemotherapy or combined modality therapy, followed by restaging to assess treatment response. PET scans are recommended to evaluate initial staging and assess treatment response at restaging. However, they are not recommended for routine surveillance. Combined modality therapy (brief course of chemotherapy and limited irradiation) is the preferred treatment for early-stage favorable CHL (stage IA-IIA nonbulky) and early-stage unfavorable CHL (stage I-II bulky). Chemotherapy alone or combined modality therapy is recommended for advanced-stage CHL (stage IB-IIB nonbulky and stage III-IV). Combined modality therapy or radiation alone is the option for early-stage LPHL. Patients with advanced-stage LPHL may be treated with more aggressive therapy. The role of chemotherapy or antibody-based therapy is being explored in ongoing clinical trials for early-and advanced-stage LPHL. HDT/ASCR is the best treatment option for patients with relapsed or refractory HL, although it does not improve overall survival. Consistent with NCCN philosophy, participation in clinical trials is always encouraged. HL is now curable in most patients because more effective, less toxic regimens have been introduced. However, survivors may experience late treatment-related side effects. For this reason, long-term follow-up by an oncologist is essential after completion of treatment. Counseling about survivorship issues and careful monitoring for late treatment-related side effects should be integral follow-up for these patients.

KW - Classical Hodgkin disease

KW - Combined modality therapy

KW - Hodgkin disease

KW - Lymphocyte predominance

KW - Lymphoma

KW - NCCN clinical practice guidelines

UR - http://www.scopus.com/inward/record.url?scp=47649124480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649124480&partnerID=8YFLogxK

M3 - Review article

VL - 6

SP - 594

EP - 622

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 6

ER -